- Nextleaf Solutions (OILS) has been granted a patent for the acetylation of cannabinoids
- The patent from the Canadian Intellectual Property Office covers a process for acetylating cannabidiol
- Nextleaf owns 12 issued U.S. patents and 70 issued patents globally for the extraction, purification, and delivery of cannabinoids
- This patented process to produce CBD-O-Acetate enables the standardization of a more potent analog of CBD through targeted drug delivery
- Nextleaf is up 5.79 per cent to C$0.36 per share
Nextleaf Solutions (OILS) has been granted a patent for the acetylation of cannabinoids.
The patent from the Canadian Intellectual Property Office covers a process for acetylating cannabidiol, and subsequent refinement of CBD-O-Acetate using a proprietary extraction and distillation technique.
Nextleaf owns 12 issued U.S. patents and 70 issued patents globally for the extraction, purification, and delivery of cannabinoids. The British Columbia-based company said this represents the second largest patent portfolio among all cannabis companies.
Nextleaf Solutions CEO Paul Pedersen said his team expects the results of the 2020 U.S. elections to have a transformational effect on the commercial value of its U.S. patent portfolio.
“The world’s largest cannabis company launching the industry’s first patent infringement lawsuit against GW Pharma on December 22, 2020 demonstrates the value of patents and intellectual property in the cannabis industry,” he added.
Last year, Canadian cannabis company Canopy Growth filed a lawsuit against UK-based GW Pharmaceuticals PLC, alleging patent infringement.
This patented process to produce CBD-O-Acetate enables the standardization of a more potent analog of CBD through targeted drug delivery. Prodrugs utilize various physical and chemical modifications to improve features of active drugs.
Nextleaf said it believes an orally consumable CBD metabolic prodrug produced under its patented process for acetylating cannabidiol will enhance the therapeutic potency of CBD.
The company’s patent portfolio and Health Canada licenses for cannabis processing and research presents an entry point for pharmaceutical firms looking to manufacture cannabinoid prodrugs in a federally legal jurisdiction.
In a press release, Nextleaf said it plans to commercialize this intellectual property through IP licensing, and the production of IP protected cannabinoid-based products as legally permitted by Health Canada.
Nextleaf has also engaged Kronos Capital Partners to pursue and evaluate global strategic partners and investors. Kronos is a strategic advisor and an active investor in the global cannabis and life science sectors.
Nextleaf is up 5.79 per cent to C$0.36 per share at 2:44pm EST.
